AGP Executive Report
Last update: an hour agoCancer Care: China dismissed two researchers after a six-year-old died in a gene-editing trial; investigators said warnings from animal studies had gone unheeded. Separately, the US FDA rejected a closely watched China-developed lung cancer drug after it failed to show a significant survival gain. Drug Access: China’s 2026 insurance list adds a record 51 innovative medicines, including the country’s first CAR-T therapy on the basic plan; the CAR-T maker says a steep price cut can still leave the treatment viable. Weight Management: Eli Lilly’s oral obesity drug won approval in China, while a Chinese weight-loss drug reported strong results in a trial, raising competition in a fast-growing treatment market. Vaccine Production: Zambia has begun building its first vaccine plant with Chinese partner Jijia, starting with capacity to fill and finish about 20 million oral cholera vaccine doses a year. Aging and Care: Government-backed “shared children” programs in several Chinese cities offer older people help at home, including assistance with medical visits and daily tasks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.